Aviragen Therapeutics (AVIR) Misses Q4 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.57), $0.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Citi downgrades Abercrombie & Fitch to neutral after 36% stock surge
• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• Cmb.Tech NV (CMBT) Tops Q2 EPS by 38c